membership growth privileg
rais estim better growth visibl reiter buy
report strong estim consensu
better revenues/margin lower tax medic loss ratio came
slightli higher expect issu appear contain medicaid market
overal boost dcp point reserv strengthen significantli rais
near-term long-term growth outlook march investor day may
wonder upsid built name think strong quarter
guidanc rais suggest still room go despit current
trade near discount averag ratio view
particularli attract buy opportun rais estim slightli follow
result po unchang base ep estim vs
previous compani deliv upsid potenti reiter buy
appear pois deliv continu upsid
medicaid issu tie state overal strong
even elev medicaid busi oper within target margin
rang addit compani indic increas part due
tough comp receiv favor period item impli
much increas could relat meanwhil compani note
confid medic manag initi abil reach target margin
fischbeck focu membership growth begin
fischbeck focu section choos theme explor detail either
respons recent investor question unexpect develop
quarter quarter focu antm freshli rais long-term ep growth guidanc
way expect deliv expect add
member averag growth prior two year even see
benefit new pharmaci benefit manag pbm agreement show
success sell specialti product close gap profit
administr servic aso risk member higher specialti penetr
estim could add upsid ep addit growth
next year new pharmaci cost structur allow continu take share
net dbt
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
total benefit claim
total invest
oper return averag asset
long term debt cap ratio ex fa
amtz dac pre-tax profit bef amtz dac
one largest manag care
organ offer
commerci larg small employ medicar
medicaid individu market compani
oper cross shield plan
buy rate reflect view
valuat undervalu compani growth
profil competit scale advantag
fischbeck focu section choos theme explor detail either
respons recent investor question unexpect develop
quarter quarter focu antm freshli rais long-term ep growth
guidanc way expect deliv expect
add member averag growth prior two year even
see benefit new pbm agreement show success sell
specialti product close gap profit aso risk member
higher specialti penetr estim could add upsid
ep addit growth next year new pharmaci cost
structur allow continu take share
shift back risk busi could drive upsid
investor day commit grow risk busi
growth came risk product signal manag track deliv
promis seen histor driven enrol growth
aso self-fund product note risk member much
profit per member basi
margin higher aso busi profit per member per month
pmpm lower sinc revenu much lower gener risk member
pmpm margin would gener profit per month meanwhil aso
member pmpm margin would gener profit per
month accordingli take five aso member gener level
profit one risk member thu continu enrol growth focu
risk mix think could deliv signific upsid leav lever
growth
chart aso vs risk enrol growth growth ahead
chart aso vs risk total medic enrol
upsel aso client could add ep
talk increas penetr specialti product vision dental stop
loss etc exist aso membership past coupl year start
make progress success would abl bridg gap
gross profit aso risk member
illustr specialti servic percentag total medic enrol
upsel risk custom well expect continu increas drive
increas earn growth note penetr rate actual much lower
chart impli one member could involv multipl product
runway still appear quit long tabl assum pmpm could go
increas upsel could add ep time
chart specialti enrol total medic enrol
tabl scenario analysi upsel specialti servic aso could add
ep
growth even new pharmaci contract kick
thing growth think impress come
even cost save new pharmaci contract kick compani
attribut growth new product offer improv broker relationship
posit compani well front see signific opportun gain
best-in-class unit cost provid commerci pharma
spend come market significantli erod competit
advantag new pharmaci contract place would expect compani
abl price aggress gain share without sacrif margin
meanwhil structur disadvantag higher pharmaci cost probabl
evid part busi antm market share well behind peer
time compani deliv cost competit part product
think also help make medicar advantag product competit
one first benefit plan give away cheap part plan final
believ better cost structur pharmaci improv compani competit
posit bid medicaid rfp result believ pois
gain addit share across product
antm growth trade discount average
expect add enrol prior two year
averag growth meanwhil next two year show averag growth
save new pbm roll final compani appear pois show
upsid membership growth next year pass back save
custom potenti growth appear price
stock current trade near discount price-
earnings-growth ratio averag view particularli attract buy
chart project grow enrol prior year member
chart ratio year-averag
conclus growth stori start
reiter buy rate thesi antm growth fulli price
compani start see reacceler membership growth
believ new pharmaci contract posit well continu growth meanwhil
compani make progress sell addit specialti servic
estim could add upsid ep time compani trade nearli
discount averag reiter buy rate
overview guidanc
histori conservat
note histor provid conserv guidanc beat
rais throughout year
tabl initi guidanc compar actual result
rais adjust ep guidanc least impli year
year growth driven result better expect revenu
growth specif administr servic aso revenu better sale
specialti valu ad servic season perspect expect
earn approach rang slightli half previou guidanc
impli estimate/consensu impli
higher consensu like due ramp save ingeniorx
reiter guidanc element provid previous includ oper
revenu trend /- /-
product sold sg /- although sg
expect increas year goe due higher invest spend includ
launch ingeniorx
product
amort
po base ep estim premium histor
averag justifi believ rel high potenti upsid
estim stand-alone
risk upsid better-than-expect enrol growth stronger growth
medicar advantag time enhanc buyback long-term benefit new
pbm risk downsid worse-than-expect membership growth rise
kevin fischbeck cfa herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us facil hospit manag healthcar coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
